Immune-Mediated Inflammatory Disease Curbside Consults: RA – What to Do After TNF Failure?
In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.
Cost: FreeView Offer chevron_right
- 0.25 AMA PRA Category 1 Credit(s)™
- The My Healio CME Dashboard keeps track of earned credits and saved activities
- Personalized recommendations make finding your next activity easy
- Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
- Rheumatoid arthritis (RA)
- Immune-mediated inflammatory disease
- Tumor necrosis factor inhibitor (TNF)
- Rheumatology; Dermatology
Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Additional credit info
This continuing medical education activity is provided by Vindico Medical Education.
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020, through October 18, 2021.